Lifecore Biomedical Inc. - Asset Resilience Ratio
Lifecore Biomedical Inc. (LFCR) has an Asset Resilience Ratio of 0.03% as of February 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2013)
This chart shows how Lifecore Biomedical Inc.'s Asset Resilience Ratio has changed over time. Check how strategically is Lifecore Biomedical Inc.'s equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Lifecore Biomedical Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LFCR company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $86.00K | 0.03% |
| Total Liquid Assets | $86.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Lifecore Biomedical Inc. maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lifecore Biomedical Inc. Industry Peers by Asset Resilience Ratio
Compare Lifecore Biomedical Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 1.95% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Lifecore Biomedical Inc. (2005–2013)
The table below shows the annual Asset Resilience Ratio data for Lifecore Biomedical Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2013-05-31 | 0.53% | $1.54 Million | $290.94 Million | -13.10pp |
| 2011-05-31 | 13.63% | $28.12 Million | $206.31 Million | +3.43pp |
| 2010-05-31 | 10.20% | $20.42 Million | $200.20 Million | -4.52pp |
| 2009-05-31 | 14.72% | $22.50 Million | $152.87 Million | +4.99pp |
| 2008-05-31 | 9.72% | $14.64 Million | $150.59 Million | +7.76pp |
| 2005-05-31 | 1.97% | $1.97 Million | $100.08 Million | -- |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more